<DOC>
	<DOCNO>NCT00707278</DOCNO>
	<brief_summary>The study prospective phase I trial radiation therapy concurrent capecitabine oxaliplatin chemotherapy treatment locally advance pancreas adenocarcinoma . Eligibility criterion include pathologically confirm , non-metastatic adenocarcinoma pancreas surgically unresectable . Patients undergo radiation therapy ( 28 treatment 1.8 Gy total 50.4 Gy ) concurrent capecitabine oxaliplatin chemotherapy . The primary objective study determine maximum tolerated dos capecitabine oxaliplatin deliver concurrently 50.4 Gy radiation therapy without surgery patient population . Secondary objective study determine tumor response rate , survival rate , local control rate rate distant metastasis follow capecitabine , oxaliplatin , radiation therapy without surgery determine rate patient unresectable disease become resectable .</brief_summary>
	<brief_title>Radiation Therapy Capecitabine/Oxaliplatin Chemotherapy Treatment Locally Advanced Pancreas Adenocarcinoma</brief_title>
	<detailed_description>Patients undergo radiation therapy ( 28 treatment 1.8 Gy total 50.4 Gy ) concurrent capecitabine oxaliplatin chemotherapy . The primary objective study determine maximum tolerated dos capecitabine oxaliplatin deliver concurrently 50.4 Gy radiation therapy without surgery patient population . Three dose level plan , show `` Dose Escalation '' table . Three patient plan level . When 3 patient complete entire chemoradiation course monitor least 2 week end treatment without occurrence dose limit toxicity ( DLTs ) , next 3 patient treat next high dose level . If one first three patient treat give dose level experience DLT , three patient treat level . If one six patient give level experience DLT , escalation proceed . If two three six patient low administer dose level experience DLTs , MTD low administer dose , specific MTD define . If two three six patient higher dose level experience DLTs , dose precede low dose level satisfy criterion declare MTD . If dose level exhaust without two three six patient experience DLTs , MTD high maximum administer dose , specific MTD define . If MTD reach give dose level , additional patient accrue next low dose level , six patient accrue dose level MTD . Because three dose level plan , 3 6 patient enrol dose level , minimum 9 maximum 18 patient require trial completion .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Patient Selection Criteria Pathologically confirm adenocarcinoma pancreas . No distant metastasis ( metastasis beyond regional lymph node ) . Deemed surgically unresectable surgical oncologist due hepatic artery , celiac axis , superior mesenteric artery , superior mesenteric vein , portal vein , aorta , inferior vena cava , and/or rib/vertebral body involvement define CT/MRI scan and/or endoscopic ultrasound ( EUS ) . No malignancy ( within past two year ) except nonmelanomatous skin cancer carcinoma situ cervix , uterus , bladder . No previous chemotherapy pancreatic cancer . No prior irradiation plan field . Zubrod performance status 01 . Granulocytes &gt; 1,800 , platelet &gt; 100,000/ul , bilirubin &lt; 2.0 mg/dL , ALT &lt; 3x upper limit normal , creatinine &lt; 3.0 mg/dL . No significant infection coexistent medical condition . No pregnant lactate woman . Age &gt; 18 year old . Signed studyspecific consent form prior registration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>